PT  - JOURNAL ARTICLE
AU  - Resta, Emanuela
AU  - Carpagnano, Giovanna Elisiana
AU  - Pelaia, Corrado
AU  - D'Amato, Maria
AU  - Crimi, Nunzio
AU  - Scichilone, Nicola
AU  - Calabrese, Cecilia
AU  - Resta, Onofrio
AU  - Scioscia, Giulia
AU  - Pelaia, Girolamo
AU  - Foschino Barbaro, Maria Pia
TI  - Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
AID  - 10.1183/13993003.congress-2020.4809
DP  - 2020 Sep 07
TA  - European Respiratory Journal
PG  - 4809
VI  - 56
IP  - suppl 64
4099  - http://erj.ersjournals.com/content/56/suppl_64/4809.short
4100  - http://erj.ersjournals.com/content/56/suppl_64/4809.full
SO  - Eur Respir J2020 Sep 07; 56
AB  - Background: Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ quality of life and increased healthcare spending.Objectives: To assess the clinical and economic impact of switching from omalizumab (OMA) to mepolizumab (MEP) in patients eligible for both biologics but not optimally controlled with OMA.Methods: Uncontrolled patients referred to 6 asthma clinics in south of Italy switched from OMA to MEP, were enrolled and followed-up to Jan 2020. Clinical information included blood eosinophil count, asthma control test (ACT), pulmonary function, IgE, exhaled nitric oxide (FeNO), OCS intake, drugs, exacerbations/hospitalizations, visits and exams. A 12-months standardized total cost per patient pre and post MEP was calculated in the perspective of Italian National Health System.Results: 33 patients were enrolled: 5 male, median age 59 years, disease onset 24 years. At OMA discontinuation, 89% were OCS-dependent with annual mean rate of 3.1 exacerbations. The switch to MEP reduced both exacerbation (-2.8) and OCS-dependent patients (-76%). Pulmonary function improved and both IgE, FENO and eosinophils serum decreased. Annual cost was €11,277 with OMA and €12,498 with MEP (p=0.2041), the increment due to biologic (+€1,673) was partially offset by the saving due to all other cost items (-€452).Conclusions: Patients with severe eosinophilic asthma not controlled by OMA experienced a clinically benefit in asthma control switching to MEP with a slight economic impact.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4809.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).